Thomas A. Lampkin

786 total citations
11 papers, 631 citations indexed

About

Thomas A. Lampkin is a scholar working on Oncology, Molecular Biology and Cell Biology. According to data from OpenAlex, Thomas A. Lampkin has authored 11 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Cell Biology. Recurrent topics in Thomas A. Lampkin's work include Microtubule and mitosis dynamics (5 papers), Cancer Treatment and Pharmacology (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Thomas A. Lampkin is often cited by papers focused on Microtubule and mitosis dynamics (5 papers), Cancer Treatment and Pharmacology (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Thomas A. Lampkin collaborates with scholars based in United States, Netherlands and United Kingdom. Thomas A. Lampkin's co-authors include Yan Degenhardt, Deborah A. Smith, Lawrence J. Hak, George E. Dukes, Timothy A. Yap, Richard H. Wilson, Sharon C. Murray, Jeffrey Botbyl, Alicia J. Allred and David Olmos and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Pharmaceutical Research.

In The Last Decade

Thomas A. Lampkin

11 papers receiving 620 citations

Peers

Thomas A. Lampkin

ONCOL

PRM

Gary Beale United Kingdom

Jamie Arnott United States

Mahesh V. Padval United States

Peter Sicinski United States

Rui-Qing Peng China

Vikas Sehdev United States

Diana E. Lamendola United States

Angelina I. Londoño-Joshi United States

N. Barry Elkind Hungary

Maribelis Ruiz United States

Gary Beale United Kingdom

Thomas A. Lampkin

418 ×1.0

200 ×0.8

ONCOL

78 ×0.3

101 ×1.2

41 ×0.5

PRM

Citations per year, relative to Thomas A. Lampkin Thomas A. Lampkin (= 1×) peers Gary Beale

Countries citing papers authored by Thomas A. Lampkin

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Lampkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Lampkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Lampkin more than expected).

Fields of papers citing papers by Thomas A. Lampkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Lampkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Lampkin. The network helps show where Thomas A. Lampkin may publish in the future.

Co-authorship network of co-authors of Thomas A. Lampkin

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Lampkin. A scholar is included among the top collaborators of Thomas A. Lampkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Lampkin. Thomas A. Lampkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Münster, Pamela N., Rahul Aggarwal, David S. Hong, et al.. (2015). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 22(8). 1932–1939. 83 indexed citations

Olmos, David, Douglas S. Barker, Rohini Sharma, et al.. (2011). Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 17(10). 3420–3430. 134 indexed citations

Chung, Vincent, Elisabeth I. Heath, William R. Schelman, et al.. (2011). First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemotherapy and Pharmacology. 69(3). 733–741. 66 indexed citations

Qian, Yongzhen, Emily Hua, Kheem S. Bisht, et al.. (2011). Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clinical & Experimental Metastasis. 28(8). 899–908. 33 indexed citations

Münster, Pamela N., Ruud van der Noll, Emile E. Voest, et al.. (2011). Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).. Journal of Clinical Oncology. 29(15_suppl). 3018–3018. 22 indexed citations

Holen, Kyle D., E. Heath, William R. Schelman, et al.. (2010). Phase I first-in-human study of the centromere-associated protein E (CENP-E) inhibitor GSK923295 in patients with advanced solid tumors (study CPE107602).. Journal of Clinical Oncology. 28(15_suppl). 3012–3012. 2 indexed citations

Degenhardt, Yan & Thomas A. Lampkin. (2010). Targeting Polo-like Kinase in Cancer Therapy. Clinical Cancer Research. 16(2). 384–389. 211 indexed citations

LoRusso, Patricia, Herbert I. Hurwitz, E. Gabriela Chiorean, et al.. (2008). AKT inhibitor GSK690693: Preliminary results from the first time in human study. 68. 7 indexed citations

Schwartz, Gary K., Thomas R. Johnson, Aaron S. Goetz, et al.. (2001). A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.. PubMed. 7(7). 1901–11. 11 indexed citations

10.

Dukes, George E., William D. Heizer, Yong Han, et al.. (1992). Influence of Gastrointestinal Site of Drug Delivery on the Absorption Characteristics of Ranitidine. Pharmaceutical Research. 9(9). 1190–1194. 53 indexed citations

11.

Lampkin, Thomas A., Danièle Ouellet, Lawrence J. Hak, & George E. Dukes. (1990). Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders. DICP. 24(4). 393–402. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact